{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:48:43Z","timestamp":1791233323811,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002910","name":"F\u00e9d\u00e9ration Wallonie-Bruxelles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002910","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024020","name":"Universit\u00e9 de Mons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024020","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bcp.2025.117448","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T19:52:02Z","timestamp":1761076322000},"page":"117448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P1","title":["Toward the development of an innovative pharmacological compound employing peptides for EGFR-mediated drug delivery in anaplastic thyroid carcinoma"],"prefix":"10.1016","volume":"243","author":[{"given":"Zehra-Cagla","family":"Kahvecioglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Vandecasteele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Bougard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Rasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Nachtergael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Duez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Nonclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Remmelink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Saussez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1117-1935","authenticated-orcid":false,"given":"Carmen","family":"Burtea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bcp.2025.117448_b0005","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a020768","article-title":"The EGFR Family: not so prototypical receptor tyrosine kinases","volume":"6","author":"Lemmon","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117448_b0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.bcp.2025.117448_b0015","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3390\/molecules27030819","article-title":"Structural insight and development of EGFR tyrosine kinase inhibitors","volume":"27","author":"Amelia","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2025.117448_b0020","doi-asserted-by":"crossref","unstructured":"A. Conte, S. Sigismund, Chapter Six - The ubiquitin network in the control of EGFR endocytosis and signaling, in: S.K. Shenoy (Ed.), Prog. Mol. Biol. Transl. Sci., vol. 141, Ubiquitination and Transmembrane Signaling, Academic Press, 2016, pp. 225\u2013276, https:\/\/doi.org\/10.1016\/bs.pmbts.2016.03.002.","DOI":"10.1016\/bs.pmbts.2016.03.002"},{"issue":"10","key":"10.1016\/j.bcp.2025.117448_b0025","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.cellsig.2007.06.023","article-title":"Mechanisms for oncogenic activation of the epidermal growth factor receptor","volume":"19","author":"Zandi","year":"2007","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.bcp.2025.117448_b0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tcb.2013.11.002","article-title":"EGF receptor trafficking: consequences for signaling and cancer","volume":"24","author":"Tomas","year":"2014","journal-title":"Trends Cell Biol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117448_b0035","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1134\/S0006297920090011","article-title":"Epidermal growth factor receptor: Key to selective intracellular delivery","volume":"85","author":"Rosenkranz","year":"2020","journal-title":"Biochemistry (Mosc.)"},{"issue":"28","key":"10.1016\/j.bcp.2025.117448_b0040","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1038\/onc.2010.157","article-title":"Nuclear trafficking of the epidermal growth factor receptor family membrane proteins","volume":"29","author":"Wang","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.117448_b0045","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/bs.mcb.2015.05.008","article-title":"Methods to study endocytic trafficking of the EGF receptor","volume":"130","author":"Pinilla-Macua","year":"2015","journal-title":"Methods Cell Biol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117448_b0050","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1074\/jbc.M117.811299","article-title":"Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation","volume":"293","author":"Tanaka","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2025.117448_b0055","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.radonc.2013.06.010","article-title":"Nuclear EGFR as a molecular target in cancer","volume":"108","author":"Brand","year":"2013","journal-title":"Radiother. Oncol."},{"issue":"19","key":"10.1016\/j.bcp.2025.117448_b0060","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1111\/febs.13342","article-title":"Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases","volume":"282","author":"Chen","year":"2015","journal-title":"FEBS J."},{"issue":"4","key":"10.1016\/j.bcp.2025.117448_b0065","doi-asserted-by":"crossref","first-page":"616","DOI":"10.37349\/etat.2023.00156","article-title":"Nuclear epidermal growth factor receptor as a therapeutic target","volume":"4","author":"Atwell","year":"2023","journal-title":"Explor. Target Antitumor Ther."},{"key":"10.1016\/j.bcp.2025.117448_b0070","doi-asserted-by":"crossref","DOI":"10.2174\/1568026620666200303123102","article-title":"Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors","volume":"20","author":"Sabbah","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117448_b0075","first-page":"393","article-title":"Epidermal growth factor mutation as a diagnostic and therapeutic target in metastatic poorly differentiated thyroid carcinoma: a case report and review of the literature, Case Rep","volume":"7","author":"Lote","year":"2014","journal-title":"Oncol"},{"issue":"24","key":"10.1016\/j.bcp.2025.117448_b0080","doi-asserted-by":"crossref","first-page":"8594","DOI":"10.1158\/1078-0432.CCR-04-0690","article-title":"Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer","volume":"10","author":"Schiff","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.bcp.2025.117448_b0085","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1111\/febs.12393","article-title":"The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered","volume":"280","author":"Gan","year":"2013","journal-title":"FEBS J."},{"issue":"7","key":"10.1016\/j.bcp.2025.117448_b0090","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/carcin\/bgm058","article-title":"EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes","volume":"28","author":"Grandal","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2025.117448_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102380","article-title":"Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era","volume":"106","author":"Capdevila","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2025.117448_b0100","first-page":"2369","article-title":"Genetic alterations in anaplastic thyroid carcinoma and targeted therapies","volume":"18","author":"Li","year":"2019","journal-title":"Exp. Ther. Med."},{"issue":"10061","key":"10.1016\/j.bcp.2025.117448_b0105","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","article-title":"Thyroid cancer","volume":"388","author":"Cabanillas","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2025.117448_b0110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fendo.2020.00102","article-title":"Update on fundamental mechanisms of thyroid cancer","volume":"11","author":"Prete","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bcp.2025.117448_b0115","unstructured":"F. Limaiem, S. Kashyap, P.T. Naing, A.O. Giwa, Anaplastic thyroid cancer, in: StatPearls, Treasure Island (FL), StatPearls Publishing, 2023. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538179\/."},{"issue":"3","key":"10.1016\/j.bcp.2025.117448_b0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11912-021-01019-9","article-title":"Lam, Anaplastic thyroid carcinoma: current issues in genomics and therapeutics","volume":"23","author":"Abe","year":"2021","journal-title":"Curr. Oncol. Rep."},{"issue":"11","key":"10.1016\/j.bcp.2025.117448_b0125","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/nrendo.2017.76","article-title":"Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies","volume":"13","author":"Molinaro","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bcp.2025.117448_b0130","doi-asserted-by":"crossref","unstructured":"W.A. Lai, C.Y. Liu, S.Y. Lin, C.C. Chen, J.F. Hang, Characterization of driver mutations in anaplastic thyroid carcinoma identifies RAS and PIK3CA mutations as negative survival predictors, Cancers (Basel) 12 (7) (2020) 1973, https:\/\/doi.org\/10.3390\/cancers12071973.","DOI":"10.3390\/cancers12071973"},{"key":"10.1016\/j.bcp.2025.117448_b0135","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fendo.2020.00082","article-title":"New therapies for advanced thyroid cancer","volume":"11","author":"Laha","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117448_b0140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13044-020-00091-w","article-title":"Recent advances in the management of anaplastic thyroid cancer","volume":"13","author":"De Leo","year":"2020","journal-title":"Thyroid Res."},{"key":"10.1016\/j.bcp.2025.117448_b0145","doi-asserted-by":"crossref","unstructured":"D. Fanfone, N. Despretz, D. Stanicki, J. Rubio-Magnieto, M. Foss\u00e9pr\u00e9, M. Surin, S. Rorive, I. Salmon, L. Vander Elst, S. Laurent, R.N. Muller, S. Saussez, C. Burtea, Toward a new and noninvasive diagnostic method of papillary thyroid cancer by using peptide vectorized contrast agents targeted to galectin-1, Med. Oncol. 34 (11) (2017) 184, https:\/\/doi.org\/10.1007\/s12032-017-1042-y.","DOI":"10.1007\/s12032-017-1042-y"},{"key":"10.1016\/j.bcp.2025.117448_b0150","doi-asserted-by":"crossref","unstructured":"S. Andr\u00e9, L. Larbanoix, S. Verteneuil, D. Stanicki, D. Nonclercq, L. Vander Elst, S. Laurent, R.N. Muller, C. Burtea, Development of an LDL receptor-targeted peptide susceptible to facilitate the brain access of diagnostic or therapeutic agents, Biology (Basel) 9 (7) (2020) 161, https:\/\/doi.org\/10.3390\/biology9070161.","DOI":"10.3390\/biology9070161"},{"key":"10.1016\/j.bcp.2025.117448_b0155","doi-asserted-by":"crossref","unstructured":"C. Burtea, S. Laurent, T. Sanli, D. Fanfone, A. Devalckeneer, S. Sauvage, M.C. Beckers, S. Rorive, I. Salmon, L. Vander Elst, B.R. Lauwerys, R.N. Muller, Screening for peptides targeted to IL-7R\u03b1 for molecular imaging of rheumatoid arthritis synovium, Arthritis Res. Ther. 18 (1) (2016) 230, https:\/\/doi.org\/10.1186\/s13075-016-1133-8.","DOI":"10.1186\/s13075-016-1133-8"},{"key":"10.1016\/j.bcp.2025.117448_b0160","doi-asserted-by":"crossref","unstructured":"C. Burtea, S. Ballet, S. Laurent, O. Rousseaux, A. Dencausse, W. Gonzalez, M. Port, C. Corot, L. Vander Elst, R.N. Muller, Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis-targeted ultrasmall superparamagnetic iron oxide derivatives, Arterioscler. Thromb. Vasc. Biol. 32 (6) (2012) e36\u201348, https:\/\/doi.org\/10.1161\/ATVBAHA.112.245415.","DOI":"10.1161\/ATVBAHA.112.245415"},{"issue":"4","key":"10.1016\/j.bcp.2025.117448_b0165","doi-asserted-by":"crossref","first-page":"C723","DOI":"10.1152\/ajpcell.00462.2010","article-title":"A practical guide to evaluating colocalization in biological microscopy","volume":"300","author":"Dunn","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.bcp.2025.117448_b0170","doi-asserted-by":"crossref","unstructured":"D. Fanfone, D. Stanicki, D. Nonclercq, M. Port, L. Vander Elst, S. Laurent, R.N. Muller, S. Saussez, C. Burtea, Molecular imaging of galectin-1 expression as a biomarker of papillary thyroid cancer by using peptide-functionalized imaging probes, Biology (Basel) 9 (3) (2020) 53, https:\/\/doi.org\/10.3390\/biology9030053.","DOI":"10.3390\/biology9030053"},{"issue":"W1","key":"10.1016\/j.bcp.2025.117448_b0180","doi-asserted-by":"crossref","first-page":"W432","DOI":"10.1093\/nar\/gkad376","article-title":"PEP-FOLD4: a pH-dependent force field for peptide structure prediction in aqueous solution","volume":"51","author":"Rey","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.bcp.2025.117448_b0190","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0092-8674(02)00963-7","article-title":"Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains","volume":"110","author":"Ogiso","year":"2002","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2025.117448_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054136","article-title":"Molecular determinants of epidermal growth factor binding: a molecular dynamics study","volume":"8","author":"Sanders","year":"2013","journal-title":"PLoS One"},{"issue":"W1","key":"10.1016\/j.bcp.2025.117448_b0185","doi-asserted-by":"crossref","first-page":"W443","DOI":"10.1093\/nar\/gky357","article-title":"HPEPDOCK: a web server for blind peptide\u2013protein docking based on a hierarchical algorithm","volume":"46","author":"Zhou","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2025.117448_b0195","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/790834","article-title":"Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer","volume":"2014","author":"Ragazzi","year":"2014","journal-title":"Int. J. Endocrinol."},{"issue":"45","key":"10.1016\/j.bcp.2025.117448_b0200","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.bcp.2025.117448_b0205","first-page":"2413","article-title":"HER2-targeted multimodal imaging of anaplastic thyroid cancer","volume":"9","author":"Wei","year":"2019","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117448_b0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bcp.2025.117448_b0215","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-3-319-96704-2_9","article-title":"EGFR trafficking in physiology and cancer","volume":"57","author":"Caldieri","year":"2018","journal-title":"Prog. Mol. Subcell. Biol."},{"key":"10.1016\/j.bcp.2025.117448_b0220","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.semcancer.2019.06.002","article-title":"Akt in cancer: mediator and more","volume":"59","author":"Revathidevi","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2025.117448_b0225","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2017.11.017","article-title":"Bad phosphorylation as target of inhibition in oncology","volume":"415","author":"Bui","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2025.117448_b0230","doi-asserted-by":"crossref","unstructured":"C. Burtea, S. Laurent, E. Lancelot, S. Ballet, O. Murariu, O. Rousseaux, M. Port, L. Vander Elst, C. Corot, R.N. Muller, Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques, Mol. Pharm. 6 (6) (2009) 1903\u20131919, https:\/\/doi.org\/10.1021\/mp900106m.","DOI":"10.1021\/mp900106m"},{"issue":"7\u20138","key":"10.1016\/j.bcp.2025.117448_b0235","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/1061186X.2019.1710840","article-title":"Modulation of adiponectin receptors AdipoR1 and AdipoR2 by phage display-derived peptides in in vitro and in vivo models","volume":"28","author":"Crombez","year":"2020","journal-title":"J. Drug Target."},{"key":"10.1016\/j.bcp.2025.117448_b0240","article-title":"Hematological and plasma biochemical values in four specific pathogen-free mice strains produced in the animal facility at Cantacuzino Institute, Bucharest","volume":"LXIV (1)","author":"Coman","year":"2018","journal-title":"Sci. Works Ser. C Vet. Med."},{"issue":"4","key":"10.1016\/j.bcp.2025.117448_b0245","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.3892\/etm.2017.4157","article-title":"Isoflurane anesthesia induces liver injury by regulating the expression of insulin-like growth factor 1","volume":"13","author":"Zhu","year":"2017","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117448_b0250","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/bja\/aen322","article-title":"Apoptotic insults to human HepG2 cells induced by S-(+)-ketamine occurs through activation of a Bax\u2013mitochondria\u2013caspase protease pathway","volume":"102","author":"Lee","year":"2009","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.bcp.2025.117448_b0255","doi-asserted-by":"crossref","unstructured":"C. Burtea, S. Laurent, T. Sanli, D. Fanfone, A. Devalckeneer, S. Sauvage, M.C. Beckers, S. Rorive, I. Salmon, L. Vander Elst, B.R. Lauwerys, R.N. Muller, Screening for peptides targeted to IL-7R\u03b1 for molecular imaging of rheumatoid arthritis synovium, Arthritis Res. Ther. 18 (1) (2016) 230, https:\/\/doi.org\/10.1186\/s13075-016-1133-8.","DOI":"10.1186\/s13075-016-1133-8"},{"key":"10.1016\/j.bcp.2025.117448_b0260","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.747324","article-title":"Interleukin-7 biology and its effects on immune cells: mediator of generation, differentiation, survival, and homeostasis","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117448_b0265","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.3390\/cells10112908","article-title":"Novel peptide therapeutic approaches for cancer treatment","volume":"10","author":"Li","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.bcp.2025.117448_b0270","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.3390\/pharmaceutics15061648","article-title":"Targeting peptides: the new generation of targeted drug delivery systems","volume":"15","author":"Todaro","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.bcp.2025.117448_b0275","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"13","key":"10.1016\/j.bcp.2025.117448_b0280","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"#cr-split#-10.1016\/j.bcp.2025.117448_b0285.1","doi-asserted-by":"crossref","unstructured":"K.C. Bible, E. Kebebew, J. Brierley, J.P. Brito, M.E. Cabanillas, T.J. Clark Jr, A. Di Cristofano, R. Foote, T. Giordano, J. Kasperbauer, K. Newbold, Y.E. Nikiforov, G. Randolph, M.S. Rosenthal, A.M. Sawka, M. Shah, A. Shaha, R. Smallridge, C.K. Wong-Clark, 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer, Thyroid 31","DOI":"10.1089\/thy.2020.0944"},{"key":"#cr-split#-10.1016\/j.bcp.2025.117448_b0285.2","doi-asserted-by":"crossref","unstructured":"(3) (2021) 337-386, https:\/\/doi.org\/10.1089\/thy.2020.0944. Erratum in: Thyroid 31","DOI":"10.1089\/thy.2020.0944"},{"key":"#cr-split#-10.1016\/j.bcp.2025.117448_b0285.3","unstructured":"(10) (2021) 1606-1607, https:\/\/doi.org\/10.1089\/thy.2020.0944.correx."},{"issue":"6","key":"10.1016\/j.bcp.2025.117448_b0290","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/er.2019-00007","article-title":"Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond","volume":"40","author":"Cabanillas","year":"2019","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2025.117448_b0295","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12943-018-0903-0","article-title":"Therapeutic advances in anaplastic thyroid cancer: a current perspective","volume":"17","author":"Saini","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2025.117448_b0300","article-title":"Immunotherapy or targeted therapy: what will be the future treatment for anaplastic thyroid carcinoma?","volume":"13","author":"Gao","year":"2023","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117448_b0305","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1039\/D0BM01832E","article-title":"Synthesis and characterization of CD133 targeted aptamer-drug conjugates for precision therapy of anaplastic thyroid cancer","volume":"9","author":"Ge","year":"2021","journal-title":"Biomater. Sci."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225007130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225007130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:00:48Z","timestamp":1775797248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225007130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":63,"alternative-id":["S0006295225007130"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117448","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward the development of an innovative pharmacological compound employing peptides for EGFR-mediated drug delivery in anaplastic thyroid carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117448","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117448"}}